OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Matthew Snape is a paediatrician who joined Moderna in 2022 to lead their Paediatric and Maternal Clinical Development team.
Prior to this he worked as the NIHR Oxford BRC Consultant in Vaccinology and Pediatrics at the Oxford Vaccine Group (University of Oxford) and the Oxford Children’s Hospital.
Research interests while at the Oxford Vaccine Group included leading phase 1 to 4 studies on vaccines against pathogens such as RSV, Ebola virus, Influenza, Pneumococcus and Meningococcus. From 2017 to 2022 he led the NIHR funded National Immunisation Schedule Evaluation Consortium (NISEC), tasked with conducting research studies of relevance to UK immunisation policy. In this role he lead the ‘COM-COV’ trials studying heterologous COVID-19 vaccine schedules
Matthew Snape is originally from Melbourne, Australia, where he trained in Paediatrics at the Royal Children’s Hospital.
